Company Filing History:
Years Active: 2020
Title: Innovations of Wei Huang in Glycoengineering
Introduction
Wei Huang is a notable inventor based in Shanghai, China. He has made significant contributions to the field of glycoengineering, particularly in the development of antibodies and their fragments. His work focuses on enhancing the efficiency of glycosylation processes, which are crucial for the functionality of therapeutic antibodies.
Latest Patents
Wei Huang holds a patent titled "Chemoenzymatic glycoengineering of antibodies and FC fragments thereof." This invention provides recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity. These mutants are designed for the synthesis of glycoproteins, where a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. The recombinant Endo-S mutants are particularly useful for efficient glycosylation remodeling of the IgG1-Fc domain, allowing for the production of different antibody glycoforms that carry structurally well-defined Fc N-glycans.
Career Highlights
Wei Huang is affiliated with the University System of Maryland, where he continues to advance research in glycoengineering. His innovative approaches have the potential to significantly impact the development of therapeutic antibodies, enhancing their efficacy and specificity.
Collaborations
One of his notable collaborators is Lai-Xi Wang, with whom he has worked on various projects related to glycoengineering and antibody development.
Conclusion
Wei Huang's contributions to the field of glycoengineering exemplify the importance of innovation in biotechnology. His patented work on recombinant Endo-S mutants represents a significant advancement in the synthesis of glycoproteins, which could lead to improved therapeutic applications.